Clinical trials: Sarcoma, Kaposi
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT03077451
- Testing
- Laboratory Biomarker Analysis, Nelfinavir Mesylate
- Where
- 12 sites in United States, South Africa and 1 more
- Volunteers
- 36 people
- Sponsor
- AIDS Malignancy Consortium
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
AIDS-related Kaposi Sarcoma, Classic Kaposi Sarcoma
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00521092
- Testing
- sunitinib malate, laboratory biomarker analysis, pharmacological study
- Sponsor
- National Cancer Institute (NCI)
Castleman Disease, Multicentric Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Background: Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV.
- Conditions
- Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
- Trial name
- NCT01441063
- Testing
- Zidovudine, Tocilizumab, Valganciclovir (VGC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
To determine the effect of Viracept in combination with modified antiretroviral therapy on the outcome of cutaneous and mucosal Kaposi's Sarcoma (KS).
- Trial name
- NCT00002185
- Testing
- Nelfinavir mesylate
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Agouron Pharmaceuticals
Sarcoma
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma.
- Trial name
- NCT00096538
- Testing
- valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Kaposi, HIV Infections
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in…
- Trial name
- NCT00002319
- Testing
- Doxorubicin hydrochloride (liposomal)
- Where
- 33 sites in United States
- Sponsor
- Sequus Pharmaceuticals
AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
This phase II trial studies how well halofuginone hydrobromide works in treating patients with human immunodeficiency virus (HIV)-related Kaposi's sarcoma.
- Trial name
- NCT00064142
- Testing
- halofuginone hydrobromide, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi s Sarcoma (KS)
Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily
A series of studies will be conducted in Sicily by a collaborative team from the U.S. National Cancer Institute and the University of Palermo to better understand the prevalence and risk factors for the newly discovered human…
- Trial name
- NCT00339937
- Where
- Italy
- Volunteers
- 4,622 people
- Sponsor
- National Cancer Institute (NCI)
Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
This protocol presents the rationale, 25-year historical review, and methods for multidisciplinary, low-risk studies of individuals referred to the NCI Viral Epidemiology Branch (VEB).
- Conditions
- Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma, Leukemia, Lymphoma
- Trial name
- NCT00001560
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells.
- Trial name
- NCT00019188
- Testing
- interleukin-12
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Classic Kaposi Sarcoma
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
- Trial name
- NCT03219671
- Testing
- Nivolumab, Ipilimumab
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Alona Zer
Hodgkin Disease, Lymphoma, Large-Cell
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
The purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies.
- Conditions
- Hodgkin Disease, Lymphoma, Large-Cell, Sarcoma, Kaposi, Lymphoma, T-Cell, Cutaneous
- Trial name
- NCT00051597
- Testing
- SGN-30 (monoclonal antibody)
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Seagen Inc.
KSHV Inflammatory Cytokine Syndrome (KICS), KSHV
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Background: KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms.
- Conditions
- KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
- Trial name
- NCT01419561
- Testing
- Zidovudine, Liposomal Doxorubicin, Valganiclovir
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Blood Donors, Acquired Immunodeficiency Syndrome
KSHV Infection in Blood Donors From Texas
To determine the seroprevalence of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) in blood donors from Texas. Also to examine the donors' demographic characteristics and to characterize the KSHV using polymerase chain…
- Conditions
- Blood Donors, Acquired Immunodeficiency Syndrome, Blood Transfusion, Herpesvirus, Kaposi Sarcoma-Associated
- Trial name
- NCT00006310
- Sponsor
- The University of Texas Health Science Center at San Antonio
Kaposi's Sarcoma
Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma
The purpose of this study is to determine the clinical response to daily Indinavir oral administration in association with a conventional chemotherapy based on cycles of systemic Vinblastine +/- Bleomycin in patients affected by…
- Trial name
- NCT01067690
- Testing
- Indinavir in association with Vinblastina +/- Bleomicina
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Barbara Ensoli, MD, PhD
Sarcoma
Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells. PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin patch works in treating patients with Kaposi's sarcoma.
- Trial name
- NCT00295984
- Testing
- nicotine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00002188
- Testing
- Alitretinoin
- Volunteers
- 27 people
- Sponsor
- Anderson Clinical Research
Sarcoma, Kaposi, HIV Infections
A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections.
- Trial name
- NCT00002262
- Testing
- Tumor Necrosis Factor
- Where
- United States
- Sponsor
- University of California, San Francisco